What is BioSpherix?
BioSpherix is a leading innovator in advanced cell and tissue culture technology, renowned for its development of Cytocentric environments designed to optimize cell care. The company's comprehensive product portfolio includes precision gas controllers, specialized incubator subchambers, and the adaptable Xvivo System, which incorporates patented self-sanitizing technology. BioSpherix is committed to delivering customizable and cost-effective solutions that enhance cell viability and improve the accuracy of research outcomes. Its primary clientele comprises organizations within the biomedical and research industries, where high-quality data and reliable results are paramount.
How much funding has BioSpherix raised?
BioSpherix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in BioSpherix
PPP
Public-Private Partnership
What's next for BioSpherix?
The recent strategic investment signals BioSpherix's transition into a scaling phase, likely focusing on expanding its market reach and further developing its proprietary technologies. With a foundation built on precision and innovation in cell culture, the company is well-positioned to capitalize on the growing demand for advanced research tools in the life sciences. Future growth may involve strategic partnerships, enhanced product development, and broader adoption of its Cytocentric solutions across global research institutions.
See full BioSpherix company page
